The latest biotech news

News and Trends 10 Oct 2024

Second biotech IPO boom of the year: what does it mean for the industry?

Discover why biotech is experiencing a second IPO boom in 2024 and what it means for the broader industry.

October 10, 2024 - 9 minutesmins - By Monica Karpinski

News and Trends 3 Oct 2024

Resolution Therapeutics raises $85 million to advance its macrophage therapy

Find out about Resolution Therapeutics’ macrophage therapy, as it just raised $85 million in a series B round.

October 3, 2024 - 7 minutesmins - By Jules Adam

News and Trends 2 Oct 2024

Niemann-Pick disease: FDA approves first two drugs in the space of a week for rare disorder

Find out all about the first two FDA drug approvals for the rare genetic disorder Niemann-Pick disease type C.

October 2, 2024 - 7 minutesmins - By Willow Shah-Neville

News and Trends 30 Sep 2024

The race for a bird flu vaccine: milestones and breakthroughs

The recent uptick in U.S. bird flu cases poses a threat to public health. Biotechs are now developing vaccines to mitigate the outbreak.

September 30, 2024 - 10 minutesmins - By Roohi Mariam Peter

News and Trends 27 Sep 2024

Aptadir Therapeutics launches to develop new class of RNA inhibitors against cancer and genetic disorders

Italian startup Aptadir Therapeutics has launched with $1.6 million to bring a new class of drugs to the clinic and a technology to be reckoned with.

September 27, 2024 - 6 minutesmins - By Roohi Mariam Peter

With its molecular clamp technology and its lead multivalent vaccine candidate targeting both RSV and hMPV, Vicebio aims to solve unmet medical needs.

News and Trends 23 Sep 2024

Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses

Discover Vicebio’s molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against RSV and hMPV.

September 23, 2024 - 9 minutesmins - By Jules Adam

News and Trends 16 Sep 2024

Vironexis’ AAV vector approach: The next frontier in cancer immunology?

Delve into Vironexis’ launch with a pipeline of 10 cancer drug candidates built around its AAV vectors platform.

September 16, 2024 - 6 minutesmins - By Jules Adam

News and Trends 12 Sep 2024

Biotech R&D crunch: The impact of the Inflation Reduction Act and economic challenges

Delve into the consequences of the Inflation Reduction Act and the broader economic conditions on biotech R&D.

September 12, 2024 - 7 minutesmins - By Jules Adam

News and Trends 11 Sep 2024

Can Europe revive its biopharma innovation leadership?

Find out if the biotech runner-up, Europe, can step up to boost research and revive its innovation leadership.

September 11, 2024 - 9 minutesmins - By Jules Adam

News and Trends 10 Sep 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Recent deals have zoned in on drugs that target long non-coding RNAs and major moves are currently being made on the R&D front.

September 10, 2024 - 5 minutesmins - By Roohi Mariam Peter

Psychedelic therapy market: FDA rejects Lykos' MDMA treatment

News and Trends 6 Sep 2024

Psychedelic therapies under scrutiny: What’s next after Lykos’ MDMA rejection?

Delve into the psychedelic-assisted therapy market and investors’ sentiment after the FDA’s decision about Lykos’ therapy.

September 6, 2024 - 8 minutesmins - By Jules Adam

News and Trends 4 Sep 2024

2024: a year of breakthroughs for endometrial cancer?

New treatments have been approved by regulators for endometrial cancer, which are regarded as major therapeutic breakthroughs.

September 4, 2024 - 7 minutesmins - By Roohi Mariam Peter

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Second biotech IPO boom of the year: what does it mean for the industry?

Resolution Therapeutics raises $85 million to advance its macrophage therapy

Niemann-Pick disease: FDA approves first two drugs in the space of a week for rare disorder

The race for a bird flu vaccine: milestones and breakthroughs

Aptadir Therapeutics launches to develop new class of RNA inhibitors against cancer and genetic disorders

Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses

Vironexis’ AAV vector approach: The next frontier in cancer immunology?

Biotech R&D crunch: The impact of the Inflation Reduction Act and economic challenges

Can Europe revive its biopharma innovation leadership?

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Psychedelic therapies under scrutiny: What’s next after Lykos’ MDMA rejection?

2024: a year of breakthroughs for endometrial cancer?

Subscribe to our newsletter to get the latest biotech news!